The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
LynchTJBellDWSordellaR. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139.
4.
HuangSFLiuHPLiLH. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res.2004;10(24):8195–8203.
5.
ParkKGotoK.A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin. 2006;22(3):561–573.
6.
ArmourA.Gefitinib in advanced non-small cell lung cancer: clinical experience in patients of Asian origin. Asia Pac J Clin Oncol. 2007;3(2):66–78.
7.
PaezJGJännePALeeJC. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science.2004;304(5676):1497–1500.
8.
PaoWMillerVZakowskiM. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA.2004;101(36):13306–13311.
9.
KosakaTYatabeYEndohH. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res.2004;64(24):8919–8923.
10.
ShigematsuHLinLTakahashiT. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst.2005;97(5):339–346.
11.
OginoSMeyerhardtJACantorM. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res.2005;11(18):6650–6656.
12.
ChoCDFisherGAHalseyJSikicBI. Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Invest New Drugs.2006;24(2):117–123.
13.
FisherGAKuoTRamseyM. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clin Cancer Res.2008;14(21):7074–7079.
14.
ZampinoMMagniEMassacesiC. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer.2007;110(4):752–758.
15.
CascinuSBerardiRSalvagniS. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicenter phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer.2008;98(1):71–76.
16.
KuoTChoCDHalseyJ. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol.2005;23(24):5613–5619.
17.
HartmannJTPintofflJPKröningH. Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: A phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO). Onkologie. 2008;31(5):237–241.
BaschEPrestrudAAHeskethPJ. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2011. J Clin Oncol.2011;29(31):4189–4198.
GelingOEichlerHG. Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289–1294.
26.
TerreyJPAaproMS. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8:281–288.
27.
CarmichaelJKeizerHJCupissolDMilliezJScheidelPSchindlerAE. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998;9(5):381–385.
28.
de WitRde BoerAC, vd LindenGHStoterGSparreboomAVerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001; 19;85(8):1099–1101.
29.
SmithIE. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol. 1993;119(6):350–354.
30.
SoukopMA. dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer. 1994;2(3):177–183.
31.
BrandiGPantaleoMAGalliC. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer2003;89(3):477–481.
SmithTJKhatcheressianJLymanGH. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205.
MarounJAAnthonyLBBlaisN. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: A consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol. 2007;14(1):13–20.
37.
BensonABAjaniJACatalanoRB. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004;22(14):2918–2926.
38.
GamelinEGamelinLBossiLQuasthoffS.Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures. Semin Oncol.2002;29(Suppl 15):21–33.
NikcevichDAGrotheyASloanJA. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7 [abstract 4009]. Proc Am Soc Clin Oncol. 2008. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32445. Accessed August 2013.
42.
LoprinziCQinRDakhilS. Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study [abstract 3501]. J Clin Oncol. 2013. http://meetinglibrary.asco.org/content/113106-132. Accessed September 13, 2013.
43.
BoyiadzisMMLebowitzPFFrameJNFojoT.Hematology-Oncology Therapy. New York. McGraw-Hill; 2007:570–578.
44.
AronoffGRBennettWMBernsJS. Drug Prescribing in Renal Failure. 5th ed.Philadelphia: American College of Physicians; 2007.
45.
DoroshowJHSynoldTWGandaraD. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: A preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol.2003;30(15 Suppl):14–19.
46.
FloydJMirzaISachs, PerryMC. Hepatotoxicity of chemotherapy. Semin Oncol.2006;33:50–67.
47.
Rubbia-BrandtLAudardVSartorettiP. Severe hepatic sinsuoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol2004;15(3):460–466.
48.
TwelvesCWhiteJHarrisAL. A Phase I pharmacokinetic and tolerability trial of ZD1839 (Iressa) in hepatically impaired patients with solid tumors [abstract 339]. Proc Am Soc Clin Oncol. 2002;21:85a.
